Cargando…

Evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias

BACKGROUND: One-year device safety and clinical outcomes of ventral hernia repair with the GORE® SYNECOR Intraperitoneal Biomaterial, a hybrid composite mesh was evaluated. METHODS: This retrospective, multicenter, case review analyzed device/procedure endpoints and patient-reported outcomes in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Linn, John G., Mallico, Eric J., Doerhoff, Carl R., Grantham, David W., Washington, Raymond G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156806/
https://www.ncbi.nlm.nih.gov/pubmed/36550313
http://dx.doi.org/10.1007/s00464-022-09803-9
_version_ 1785036617607544832
author Linn, John G.
Mallico, Eric J.
Doerhoff, Carl R.
Grantham, David W.
Washington, Raymond G.
author_facet Linn, John G.
Mallico, Eric J.
Doerhoff, Carl R.
Grantham, David W.
Washington, Raymond G.
author_sort Linn, John G.
collection PubMed
description BACKGROUND: One-year device safety and clinical outcomes of ventral hernia repair with the GORE® SYNECOR Intraperitoneal Biomaterial, a hybrid composite mesh was evaluated. METHODS: This retrospective, multicenter, case review analyzed device/procedure endpoints and patient-reported outcomes in patients treated for hernia repair ≥ 1 year from study enrollment. RESULTS: Included were 459 patients (with 469 ventral hernias) with a mean age of 58 ± 15 years; 77.1% met Ventral Hernia Working Group 2 (VHWG2) classification. Mean hernia size was 18.9 cm(2) and 57.3% of hernias were incisional. Laparoscopic or robotic approach was utilized in 95.4% of patients. Mesh location was intraperitoneal for 75.6% and bridging repair was performed in 57.3%. Procedure-related adverse events within 30-days occurred in 5.0% of patients and included surgical site infection (SSI), surgical site occurrence (SSO), ileus, readmission, and re-operation. Procedure-related SSI or SSO events were 3.8% through 12 months. SSO events requiring procedural intervention (SSOPI) were 2.6% through 24 months. Four patients (0.9%) had confirmed hernia recurrence through the study (the mean follow-up was 32-months, range 14–53 months). Subgroup comparisons were conducted for all type recurrence; only diabetes was found to be statistically significant (p = .0506). CONCLUSION: In this analysis, ventral hernia repair with hybrid, composite mesh results in successful outcomes in most patients. This study represents a heterogeneous patient population undergoing repair using various approaches, mesh fixation, and mesh placement locations. These data appear to confirm long-term acceptable safety and device performance with a low rate of recurrence in a predominantly VHWG2 population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00464-022-09803-9.
format Online
Article
Text
id pubmed-10156806
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-101568062023-05-05 Evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias Linn, John G. Mallico, Eric J. Doerhoff, Carl R. Grantham, David W. Washington, Raymond G. Surg Endosc Article BACKGROUND: One-year device safety and clinical outcomes of ventral hernia repair with the GORE® SYNECOR Intraperitoneal Biomaterial, a hybrid composite mesh was evaluated. METHODS: This retrospective, multicenter, case review analyzed device/procedure endpoints and patient-reported outcomes in patients treated for hernia repair ≥ 1 year from study enrollment. RESULTS: Included were 459 patients (with 469 ventral hernias) with a mean age of 58 ± 15 years; 77.1% met Ventral Hernia Working Group 2 (VHWG2) classification. Mean hernia size was 18.9 cm(2) and 57.3% of hernias were incisional. Laparoscopic or robotic approach was utilized in 95.4% of patients. Mesh location was intraperitoneal for 75.6% and bridging repair was performed in 57.3%. Procedure-related adverse events within 30-days occurred in 5.0% of patients and included surgical site infection (SSI), surgical site occurrence (SSO), ileus, readmission, and re-operation. Procedure-related SSI or SSO events were 3.8% through 12 months. SSO events requiring procedural intervention (SSOPI) were 2.6% through 24 months. Four patients (0.9%) had confirmed hernia recurrence through the study (the mean follow-up was 32-months, range 14–53 months). Subgroup comparisons were conducted for all type recurrence; only diabetes was found to be statistically significant (p = .0506). CONCLUSION: In this analysis, ventral hernia repair with hybrid, composite mesh results in successful outcomes in most patients. This study represents a heterogeneous patient population undergoing repair using various approaches, mesh fixation, and mesh placement locations. These data appear to confirm long-term acceptable safety and device performance with a low rate of recurrence in a predominantly VHWG2 population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00464-022-09803-9. Springer US 2022-12-22 2023 /pmc/articles/PMC10156806/ /pubmed/36550313 http://dx.doi.org/10.1007/s00464-022-09803-9 Text en © The Author(s) 2022, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Linn, John G.
Mallico, Eric J.
Doerhoff, Carl R.
Grantham, David W.
Washington, Raymond G.
Evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias
title Evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias
title_full Evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias
title_fullStr Evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias
title_full_unstemmed Evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias
title_short Evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias
title_sort evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156806/
https://www.ncbi.nlm.nih.gov/pubmed/36550313
http://dx.doi.org/10.1007/s00464-022-09803-9
work_keys_str_mv AT linnjohng evaluationoflongtermperformanceofanintraperitonealbiomaterialinthetreatmentofventralhernias
AT mallicoericj evaluationoflongtermperformanceofanintraperitonealbiomaterialinthetreatmentofventralhernias
AT doerhoffcarlr evaluationoflongtermperformanceofanintraperitonealbiomaterialinthetreatmentofventralhernias
AT granthamdavidw evaluationoflongtermperformanceofanintraperitonealbiomaterialinthetreatmentofventralhernias
AT washingtonraymondg evaluationoflongtermperformanceofanintraperitonealbiomaterialinthetreatmentofventralhernias